Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | NEU4 | Q8WWR8 | 1/20 | 0.30 |
| ▸ | NEU1 | Q99519 | 1/20 | 0.30 |
| ▸ | FASN | P49327 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20688097 | 1.00 | CHRNB4 (0.33) | CHRNB4CHRNA3MTNR1AMTNR1BCYP1A2 | |
| SCHEMBL20696888 | 1.00 | CHRNB4 (0.33) | CHRNB4CHRNA3MTNR1AMTNR1BCYP1A2 | |
| SCHEMBL20688098 | 1.00 | CHRNB4 (0.33) | CHRNB4CHRNA3MTNR1AMTNR1BCYP1A2 | |
| SCHEMBL20688434 | 1.00 | CHRNB4 (0.33) | CHRNB4CHRNA3MTNR1AMTNR1BCYP1A2 | |
| SCHEMBL621014 | 0.88 | TAS1R3 (0.38) | CHRNB4CHRNA3ATM | |
| SCHEMBL16373137 | 0.88 | PTGS1 (0.38) | CHRNB4CHRNA3ATM | |
| SCHEMBL19755664 | 0.88 | PTGS1 (0.38) | CHRNB4CHRNA3ATM | |
| SCHEMBL21100961 | 0.88 | PTGS1 (0.38) | CHRNB4CHRNA3ATM | |
| SCHEMBL18347952 | 0.88 | TAS1R3 (0.38) | CHRNB4CHRNA3ATM | |
| SCHEMBL13380101 | 0.88 | PTGS1 (0.38) | CHRNB4CHRNA3ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024026486-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024026484-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024026479-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| US-11046698-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-10562906-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190241576-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-08 | — | — | US | disclosed |
| US-20190241575-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-08 | — | — | US | disclosed |
| US-20190031664-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046698-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | CHRNB4 3883/4885CHRNA3 3424/4885MTNR1A 3366/4885 |
| US-20190031664-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | CHRNB4 3883/4885CHRNA3 3424/4885MTNR1A 3366/4885 |
| US-10562906-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | CHRNB4 3883/4885CHRNA3 3424/4885MTNR1A 3366/4885 |
| US-20190241576-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | CHRNB4 3883/4885CHRNA3 3424/4885MTNR1A 3366/4885 |
| US-20190241575-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | CHRNB4 3883/4885CHRNA3 3424/4885MTNR1A 3366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.